Apheresis Market By Product Type (Apheresis Machine And Disposable), By Technology (Centrifugation And Membrane Filtration), By Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis And Others), By Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Automune Disorders, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to the rising increasing prevalence of hematological disorders and rise in the requirement of source plasma by various biopharmaceutical companies
The global apheresis market was valued at USD 2,230.66 million in 2021 and is estimated to grow at a CAGR of 8.75% during the forecast period (2023–2028) to reach USD 3,671.55 million by 2028. The apheresis market is slated to witness prosperity owing to factors such as the increasing prevalence of hematological disorders such as sickle cell anemia, blood cancers among others, the rise in the requirement of source plasma by various biopharmaceutical companies and an increase in the launch and approval of apheresis systems during the forecast period (2023-2028).
Apheresis Market Dynamics:
Among the noteworthy drivers of the apheresis market, the rising prevalence of hematological disorders turns out to be the major factor for accelerating the apheresis market.
For example, as per the data published by the World Health Organization (2023), anemia is a serious global public health problem that affects both young children and pregnant women. WHO estimates are in accordance with recent studies, and observes that about 42% of children less than 5 years of age and about 40% of the pregnant women are anemic globally.
Moreover, as per the National Cancer Institute 2022 (NCI), it has been estimated that there will be around 60,650 new cases of leukemia in the United States in 2022.
The report by Global Blood Therapeutics 2020 showed that sickle cell disease affected more than 52,000 people living in Europe in 2019. As per the same source, the condition carries a life expectancy of about 25 to 30 years below the general population and tends to predominantly affect the African, Mediterranean and the South Asian descent people.
Henceforth, the increasing prevalence of hematological disorders, will increase the demand for apheresis devices, which is anticipated to propel the overall market growth of the apheresis devices in the study period of 2022 – 2028.
Another major driver pertaining to the apheresis market is the development of innovative apheresis devices for the management and treatment of various diseases.
For example, in May 2021, Baxter International Inc., announced the global launch of PrisMax 2, the latest version of the company’s next-generation platform. PrisMax 2 is designed for therapeutic plasma exchange therapy and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU).
Furthermore, in April 2020, Terumo BCT, Inc. and Marker Therapeutics AG announced that the US FDA has issued Emergency Use Authorization for the use of Terumo BCT's Spectra Optia™ Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed COVID-19.
However, high costs and the various risks associated with apheresis treatment may act as restraining factors for the apheresis market growth.
The apheresis market reported a period of positive growth during the COVID-19 pandemic. Owing to rise in the COVID-19 cases, various coagulation parameters such as the platelet count, fibrinogen, D-dimmer, prothrombin time (PT), activated partial thromboplastin time (aPTT), were found as a complication among the patients that were severely infected, thus extensive applications pertaining to plasma therapies were given. The convalescent plasma therapy is used in patients that got infected due to COVID-19. Moreover, as per the article published in the Lancet Journal, between May 28, 2020 and June 15, 2021, 11558 (71%) of 16287 patients enrolled in recovery were eligible to receive convalescent plasma. CP therapy involves the collection of plasma from the patient’s body who has recently recovered from infection and infusion of that collected plasma into the body of the individuals that are at a risk. Thus, all these factors had positively impacted the growth of the global apheresis market during the pandemic.
With large number of masses being vaccinated and with the resumption of activities across industries including the healthcare sector, the apheresis market is further expected to grow positively during the forecast period from 2023-2028.
Apheresis Market Segment Analysis:
Apheresis Market by Product Type (Apheresis machines and Disposables), Technology (Centrifugation and Membrane filtration), Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Others), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)
Based on the product type segment of the apheresis market, the disposables category is projected to register a significant growth in revenue and was valued at USD 1,376.18 million in 2021 and will grow at a CAGR of 8.26% during the forecast period (2023–2028) to reach USD 2,204.25 million by 2028.
This can be can be attributed to the increased consumption of disposables in the process of apheresis. The disposables present in apheresis machines are manufactured and designed exclusively for one-time use, in order to ensure contamination-free transfer of blood components and maintain sterile conditions. Disposables form a key component for any apheresis system to deliver quality treatment, because of which all the key market players ensure a strong disposable kit profile for their apheresis systems. The Plasmat Futura Kit from B. Braun Melsungen AG, LIFE 21® and LIFE 18™ apheresis units disposables from Miltenyi Biotec, disposable TPE 2000 Set for PRISMAFLEX System from Baxter are some of the examples of quality disposables manufactured by key companies in order to build and flourish their market for apheresis.
In addition, recent developments by big market players in order to expand their expertise to more advanced disposable systems is further expected to boost the demand for disposables. For example, in January 2020, Fresenius Kabi AG inaugurated the expansion of the company’s production site in Dominican Republic, having advanced production equipment, plasma kit assembly lines and sterilization units, enabling the company to meet the rising demand for high-quality disposables.
Hence, the interplay of all the aforementioned factors is anticipated to propel the market for disposables in the upcoming years.
North America is expected to dominate the overall Apheresis Market:
Among all the regions, North America is expected to lead in revenue generation in the global apheresis market and was valued at USD 979.12 million in 2021. It will grow at a CAGR of 8.44% during the forecast period from 2023 to 2028 to reach USD 1,584.64 million by 2028.
This domination is due to the rising prevalence of chronic diseases and cancers in the region. Moreover, the increase in the number of complex surgical procedures and the rising demand for blood components will also aid in the growth of apheresis market in the North America region.
According to the figures provided by American Cancer Society 2022, it is estimated that there will be nearly 60,650 news cases of leukemia in the year 2022 in the United States. As per the National Cancer Institute 2022, in the year 2019, there were an estimated 472,714 people living with leukemia in the United States. The above statics clearly indicates that the incidence of leukemia is surging every year.
White blood cell reduction apheresis is primarily used as a treatment for patients with leukemia whose blood white cell counts are excessively high. Thus, the increasing prevalence of leukemia in the United Sates will increase the demand of apheresis in the market.
The American Association for the Surgery of Trauma reports that in the United States, injury accounts for over 150,000 deaths and over 3 million non-fatal injuries per year. The injuries undergo some sort of surgical procedure for its treatment or management. Surgical procedure are usually accompanied with blood or blood components transfusion and the blood components can be separated and stored with the aid of apheresis. Therefore, the increasing number of injuries will shoot up the number of surgical procedures, thereby increasing the demand of blood component transfusion, henceforth propelling the demand for apheresis in the market.
Therefore, along with the presence of large number of geriatric patients prone to chronic disorders in North America and the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the apheresis market in the overall North America region during the forecast period.
Apheresis Market Key Players:
Some of the key market players operating in the apheresis market include Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter International, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V & Co., KG, Haier Inc., Otsuka Holdings and others.
Recent Developmental Activities in Apheresis Market:
- In June 2022, Terumo, a medical technology company, announces that the UK’s NHS England has selected the Spectra Optia® Apheresis System through the NHS MedTech Funding Mandate to treat sickle cell disease. As a result, Spectra Optia will be deployed more widely in hospitals across England.
- In May 2021, Terumo, a medical technology company, announces that the UK’s NHS England has selected the Spectra Optia® Apheresis System through the NHS MedTech Funding Mandate to treat sickle cell disease. As a result, Spectra Optia will be deployed more widely in hospitals across England.
- In January 2020, Fresenius Kabi unveiled €30 million expansion of transfusion and apheresis disposables plant in Dominican Republic. The top government and company officials joined local executives and employees for the company’s production site in the Dominican Republic.
Key Takeaways from the Apheresis Market Report Study
- Market size analysis for current apheresis market size (2023), and market forecast for 5 years (2023-2028)
- The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the apheresis market.
- Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
- Key companies dominating the global apheresis market.
- Various opportunities available for the other competitor in the apheresis market space.
- What are the top performing segments in 2022? How these segments will perform in 2028.
- Which is the top-performing regions and countries in the current apheresis market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for apheresis market growth in the coming future?
Target Audience who can be benefited from this Apheresis Market Report Study
- Apheresis products providers
- Research organizations and consulting companies
- Apheresis-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders dealing in apheresis machines and disposables
- Various end users who want to know more about the apheresis market and latest technological developments in the apheresis market.
Frequently Asked Questions for Apheresis Market:
1. What is apheresis?
Apheresis is a medical technology used to separate various constituents of the blood, in which the remaining components of the blood are returned to the patient after extraction of the desired component (viz. erythrocytes, leukocytes, plasma, platelets etc.).
2. What is the market for the global Apheresis?
The global apheresis market was valued at USD 2,230.66 million in 2021 and is estimated to grow at a CAGR of 8.75% during the forecast period (2023–2028) to reach USD 3,671.55 million by 2028.
3. What are the drivers for the global Apheresis market?
The apheresis market is slated to witness prosperity owing to factors such as the increasing prevalence of hematological disorders such as sickle cell, anemia, blood cancers among others, the rise in the requirement of source plasma by various biopharmaceutical companies and an increase in the launch and approval of apheresis systems during the forecast period (2023-2028).
4. Who are the key players operating in the global Apheresis market?
Some of the key market players operating in the Apheresis market include Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter International, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V & Co., KG, Haier Inc., Otsuka Holdings and others.
5. Which region has the highest share in the Apheresis market?
North America is expected to dominate the overall apheresis market during the forecast period, 2023 to 2028. This can be ascribed to the rising prevalence of chronic diseases and cancers in the region. Moreover, the increase in the number of complex surgical procedures and the rising demand for blood components will also aid in the growth of the apheresis market in the North America region.